Cytomegalovirus infection in liver transplant recipients

Updates on clinical management

Jasmine Riviere Marcelin, Elena Beam, Raymund R Razonable

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection is a common complication after liver transplantation, and it is associated with multiple direct and indirect effects. Management of CMV infection and disease has evolved over the years, and clinical guidelines have been recently updated. Universal antiviral prophylaxis and a pre-emptive treatment strategy are options for prevention. A currently-recruiting randomized clinical trial is comparing the efficacy and safety of the two prevention strategies in the highest risk D+R- liver recipients. Drug-resistant CMV infection remains uncommon but is now increasing in incidence. This highlights the currently limited therapeutic options, and the need for novel drug discoveries. Immunotherapy and antiviral drugs with novel mechanisms of action are being investigated, including letermovir (AIC246) and brincidofovir (CMX001). This article reviews the current state of CMV management after liver transplantation, including the updated practice guidelines, and summarizes the data on investigational drugs and vaccines in clinical development.

Original languageEnglish (US)
Pages (from-to)10658-10667
Number of pages10
JournalWorld Journal of Gastroenterology
Volume20
Issue number31
DOIs
StatePublished - Aug 21 2014

Fingerprint

Cytomegalovirus Infections
Liver Transplantation
Antiviral Agents
Liver
Investigational Drugs
Drug Discovery
Cytomegalovirus
Practice Guidelines
Immunotherapy
Vaccines
Randomized Controlled Trials
Guidelines
Safety
Incidence
Therapeutics
Pharmaceutical Preparations
Transplant Recipients
cidofovir hexadecyloxypropyl ester
AIC246

Keywords

  • Brincidofovir
  • Cytomegalovirus
  • Investigational
  • Letermovir
  • Liver transplantation
  • Prophylaxis
  • Resistance
  • Treatment
  • Valganciclovir

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cytomegalovirus infection in liver transplant recipients : Updates on clinical management. / Marcelin, Jasmine Riviere; Beam, Elena; Razonable, Raymund R.

In: World Journal of Gastroenterology, Vol. 20, No. 31, 21.08.2014, p. 10658-10667.

Research output: Contribution to journalArticle

@article{ed970d0ad8864912983e6c54352709ce,
title = "Cytomegalovirus infection in liver transplant recipients: Updates on clinical management",
abstract = "Cytomegalovirus (CMV) infection is a common complication after liver transplantation, and it is associated with multiple direct and indirect effects. Management of CMV infection and disease has evolved over the years, and clinical guidelines have been recently updated. Universal antiviral prophylaxis and a pre-emptive treatment strategy are options for prevention. A currently-recruiting randomized clinical trial is comparing the efficacy and safety of the two prevention strategies in the highest risk D+R- liver recipients. Drug-resistant CMV infection remains uncommon but is now increasing in incidence. This highlights the currently limited therapeutic options, and the need for novel drug discoveries. Immunotherapy and antiviral drugs with novel mechanisms of action are being investigated, including letermovir (AIC246) and brincidofovir (CMX001). This article reviews the current state of CMV management after liver transplantation, including the updated practice guidelines, and summarizes the data on investigational drugs and vaccines in clinical development.",
keywords = "Brincidofovir, Cytomegalovirus, Investigational, Letermovir, Liver transplantation, Prophylaxis, Resistance, Treatment, Valganciclovir",
author = "Marcelin, {Jasmine Riviere} and Elena Beam and Razonable, {Raymund R}",
year = "2014",
month = "8",
day = "21",
doi = "10.3748/wjg.v20.i31.10658",
language = "English (US)",
volume = "20",
pages = "10658--10667",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "31",

}

TY - JOUR

T1 - Cytomegalovirus infection in liver transplant recipients

T2 - Updates on clinical management

AU - Marcelin, Jasmine Riviere

AU - Beam, Elena

AU - Razonable, Raymund R

PY - 2014/8/21

Y1 - 2014/8/21

N2 - Cytomegalovirus (CMV) infection is a common complication after liver transplantation, and it is associated with multiple direct and indirect effects. Management of CMV infection and disease has evolved over the years, and clinical guidelines have been recently updated. Universal antiviral prophylaxis and a pre-emptive treatment strategy are options for prevention. A currently-recruiting randomized clinical trial is comparing the efficacy and safety of the two prevention strategies in the highest risk D+R- liver recipients. Drug-resistant CMV infection remains uncommon but is now increasing in incidence. This highlights the currently limited therapeutic options, and the need for novel drug discoveries. Immunotherapy and antiviral drugs with novel mechanisms of action are being investigated, including letermovir (AIC246) and brincidofovir (CMX001). This article reviews the current state of CMV management after liver transplantation, including the updated practice guidelines, and summarizes the data on investigational drugs and vaccines in clinical development.

AB - Cytomegalovirus (CMV) infection is a common complication after liver transplantation, and it is associated with multiple direct and indirect effects. Management of CMV infection and disease has evolved over the years, and clinical guidelines have been recently updated. Universal antiviral prophylaxis and a pre-emptive treatment strategy are options for prevention. A currently-recruiting randomized clinical trial is comparing the efficacy and safety of the two prevention strategies in the highest risk D+R- liver recipients. Drug-resistant CMV infection remains uncommon but is now increasing in incidence. This highlights the currently limited therapeutic options, and the need for novel drug discoveries. Immunotherapy and antiviral drugs with novel mechanisms of action are being investigated, including letermovir (AIC246) and brincidofovir (CMX001). This article reviews the current state of CMV management after liver transplantation, including the updated practice guidelines, and summarizes the data on investigational drugs and vaccines in clinical development.

KW - Brincidofovir

KW - Cytomegalovirus

KW - Investigational

KW - Letermovir

KW - Liver transplantation

KW - Prophylaxis

KW - Resistance

KW - Treatment

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=84909591974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909591974&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i31.10658

DO - 10.3748/wjg.v20.i31.10658

M3 - Article

VL - 20

SP - 10658

EP - 10667

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 31

ER -